Table 1.
Patient Demographic Characteristics
| FDC (n=3301) | ARB+CCB (n=13204) | P Value | |
|---|---|---|---|
| Age, mean±SD, y | 60.30±12.53 | 60.37±13.09 | .767 |
| Male, % | 1724 (52.23) | 6861 (51.96) | .785 |
| Duration of follow‐up, mo | 15.23±3.93 | 15.27±4.11 | .627 |
| Baseline comorbid conditions, % | |||
| Coronary heart disease | 590 (17.87) | 2280 (17.27) | .411 |
| Peripheral vascular disease | 38 (1.15) | 132 (1.00) | .441 |
| Congestive heart failure | 24 (0.73) | 81 (0.61) | .463 |
| Dyslipidemia | 1097 (33.23) | 4478 (33.91) | .459 |
| Diabetes | 1101 (33.35) | 4434 (33.58) | .805 |
| Obesity | 24 (0.73) | 104 (0.79) | .723 |
| Chronic kidney disease | 117 (3.54) | 428 (3.24) | .384 |
| Baseline concomitant medications, % | |||
| ACE inhibitor‐mono | 550 (16.66) | 3381 (25.61) | <.001 |
| ACE inhibitor‐combo | 249 (7.54) | 285 (2.16) | <.001 |
| Angiotensin receptor blocker | 605 (18.33) | 4034 (30.55) | <.001 |
| β‐Blockers | 1331 (40.32) | 5209 (39.45) | .360 |
| Calcium channel blocker | 2146 (65.01) | 9307 (70.49) | <.001 |
| Diuretics | 580 (17.57) | 2781 (21.06) | <.001 |
| Other antihypertensive agents | 321 (9.72) | 1213 (9.19) | .341 |
| Antidiabetic agents | 1037 (31.42) | 3985 (30.18) | .168 |
| Overall pill burden | 419.31±478.83 | 427.17±477.35 | .398 |
Abbreviations: ACE inhibitor‐combo, angiotensin‐converting enzyme inhibitor in combination with other antihypertensive agents in a single pill; ACE inhibitor‐mono, angiotensin‐converting enzyme inhibitor only in a pill; ARB+CCB, free combinations of angiotensin receptor blockers and calcium channel blockers; FDC, fixed‐dose combination of amlodipine/valsartan; SD, standard deviation.